Stock Market
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
By Bullbit Editorial ยท March 26, 2026
- WhatSarepta shares surged **35%** after Morgan Stanley raised its price target.
- WhyThe hike was driven by stellar trial results and a positive outlook on the company's gene therapy pipeline.
- SignalThe stock's significant gain is a strong signal to investors that Sarepta's gene therapy is gaining traction.
- TargetMorgan Stanley's new price target indicates a high level of confidence in the company's future growth prospects.
- RiskThe stock's rapid ascent may pose a risk to investors who have not yet adjusted their portfolios.
More breaking news โ